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Abstract
Alzheimer’s disease (hereafter AD) is a progressive neurodegenerative disorder that affects the central nervous 
system. There are multiple factors that cause AD, viz., accumulation of extracellular Amyloid-beta 42 plaques, 
intracellular hyper-phosphorylated Tau tangles, generation of reactive oxygen species due to mitochondrial 
dysfunction and genetic mutations. The plaques and tau tangles trigger aberrant signaling, which eventually cause cell 
death of the neurons. As a result, there is shrinkage of brain, cognitive defects, behavioral and psychological 
problems. To date, there is no direct cure for AD. Thus, scientists have been testing various strategies like screening 
for the small inhibitor molecule library or natural products that may block or prevent onset of AD. Historically, natural 
products have been used in many cultures for the treatment of various diseases. The research on natural products 
have gained importance as the active compounds extracted from them have medicinal values with reduced side 
effects, and they are bioavailable. The natural products may target the proteins or members of signaling pathways that 
get altered in specific diseases. Many natural products are being tested in various animal model systems for their role 
as a potential therapeutic target for AD, and to address questions about how these natural products can rescue AD or 
other neurodegenerative disorders. Some of these products are in clinical trials and results are promising because of 
their neuroprotective, anti-inflammatory, antioxidant, anti-amyloidogenic, anticholinesterase activities and easy 
availability. This review summarizes the use of animal model systems to identify natural products, which may serve as 
potential therapeutic targets for AD. 
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In 1906, Dr. Alois Alzheimer, first described shrinkage of the brain in the autopsy of the patient who suffered from 
increasing short-term memory loss, paranoia and deteriorating cognitive abilities. In 1968, the damaged brain tissue in 
elderly subjects was measured using the newly developed cognitive measurement scales (Tomlinson et al., 1968). 
Alzheimer’s disease (AD), a senile dementia, is an age-related neurodegenerative disorder. Based on the time and 
cause of onset of AD, epidemiologists have clinically divided AD into: the early onset before 65 years, late-onset group 
consist of patients with the age 65 or above and familial AD (Rajan et al., 2018). The prevalence of AD in 2017 is 44 
million worldwide. It is estimated to be around 75 million worldwide in 2030 (Selkoe and Hardy, 2016). AD is the sixth 
leading cause of mortality. It is estimated that AD will be a global epidemic by 2050, when the number of individuals 
affected by AD will soar to 135 million (Alzheimer’s Association, 2018). AD manifests in the patients as declining 
cognitive and mental abilities due to the loss of neurons in the hippocampus and the cortex (Hardy, 2009; Sarkar et 
al., 2016). Neurons communicate with each other via synapses, which makes it plausible to recall the memories. The 
loss of synapses in AD results in loss of learning and memory. Clinically, AD patients face difficulty in short term 
memory, word finding, and language, which results in memory loss and slow progression of cognitive impairment 
(Albert et al., 2011).
AD is caused by multiple mechanisms including excessive accumulation of extracellular amyloid-beta 42 (Aβ42) 
plaques, intracellular hyper-phosphorylated tau neurofibrillary tangles in the brain, oxidative stress due to 
mitochondrial dysfunction, and/ or genetic as well as the environmental factors [Figure 1] and [Figure 2] (Selkoe and 
Podlisny, 2002; Hardy, 2009; Sarkar et al., 2016; Selkoe and Hardy, 2016; Sierra-Fonseca and Gosselink, 2018). 
Genetically the mutation in apolipoprotein E, which regulates the lipid homeostasis and carries the cholesterol to 
neurons, is a risk factor for the late-onset of AD. Oxidative stress results from generation of reactive oxygen species 
(ROS) (Chen et al., 2012; Sarkar et al., 2016). The Aβ42 plaques can form due to inappropriate cleavage of Amyloid 
precursor protein (APP), a transmembrane glycoprotein, encoded by the APP gene on chromosome 21. Generally, 
APP is cleaved proteolytically by α-secretase and γ-secretase to form 40 amino acid long peptide, however, when 
miscleaved by β-secretase and γ-secretase results in Aβ42 polypeptides [Figure 3]A (O’Brien and Wong, 2010; 
Selkoe and Hardy, 2016). These misfolded Aβ42 polypeptides accumulate to form amyloid plaques, which triggers 
neurodegeneration by activating aberrant signaling [Figure 3]B (Shankar et al., 2008; O’Brien and Wong, 2010; 
Fernandez-Funez et al., 2013; Sarkar et al., 2016; Selkoe and Hardy, 2016). Hyper-phosphorylation of tau, a protein 
involved in the stability of microtubules, decreases tau’s association to microtubules, results in accumulation of toxic 
insoluble intracellular neurofibrillary tangles [Figure 1] (Gendron and Petrucelli, 2009; Sierra-Fonseca and Gosselink, 
2018). The existing clinical regimen for AD offer transient symptomatic improvement but offer little or no benefit in 
terms of changing the overall course of disease. Lately, there have been disappointing results from AD drug trials 
(Goldman et al., 2018). These widespread AD drug trial failures are due to lack of diversity in novel targets and a lack 
of reliable and effective preclinical models. It is imperative that there is a need for a more robust, diversified drug 
development pipeline and screening animal models to find cures for AD.{Figure 1}{Figure 2}{Figure 3}
 Animal Models
The genetic machinery is highly conserved across the species. As a result, several animal models for AD have been 
developed to understand the mechanism of disease progression, and to test the potential targets of AD (Pandey and 
Nichols, 2011; Fernandez-Funez et al., 2013; Saito and Saido, 2014; Sarkar et al., 2016). Among vertebrates, the 
mouse model has been used extensively since they have similarities with the human brain (Di Carlo, 2012; Sasaguri 
et al., 2017). Both loss-of-function and gain-of-function mouse models have been generated using the genes 
responsible for AD. Early AD mouse model was generated where mutant APP was expressed that progressively 
manifested AD neuropathology (Games et al., 1995). Later, a combination type model system including Tau and 
Psen1 was generated in APP mouse background (Oddo et al., 2003). It was modified further where human sequence 
was introduced into the APP mouse to better understand AD pathology in humans (Saito et al., 2014). These model 
systems helped in discerning the learning and memory defects associated with AD by using behavioral assays. One of 
the major challenges was lack of concordance between preclinical models and human clinical trials (LaFerla and 
Green, 2012). As a result the drugs, which successfully inhibited the amyloid plaques in mice, failed to cure AD in 
humans (King, 2018). Majority of the data generated in mouse was from young animals, when their immune system is 
robust unlike the old ones. Thus, mouse models reflects early stages of AD. The reason clinical trial are failing 
because drugs that target Aβ42 in mouse model most probably treat early plaque build-up process rather than late, 
which is unlike the stage when AD is detected in humans. Thus, those drugs might fit prevention than treatment 
paradigm (King, 2018).
The other common animal models to study underlying mechanisms of AD are Drosophila melanogaster (fruit fly), 
Caenorhabditis elegans (worm), Danio rerio (zebrafish), and sea urchins (Iijima and Iijima-Ando, 2008; Iijima-Ando 
and Iijima, 2010; Pandey and Nichols, 2011; Singh, 2012; Singh and Irvine, 2012; Fernandez-Funez et al., 2013; 
Prussing et al., 2013; Saito and Saido, 2014; Sarkar et al., 2016). Caenorhabditis elegans, a nematode, has short life-
span, and has been established as a simple genetic model system (Di Carlo, 2012; LaFerla and Green, 2012). 
Transgenic lines were generated in nematode to study Aβ toxicity by using learning and behavior assays (Steinkraus 
et al., 2008). Zebrafish is a good genetic model system due to its optical clarity during developmental process of 
embryogenesis (Di Carlo, 2012), and genome is sequenced. This zebrafish possess genes orthologous to those 
mutated in familial AD, which makes it a useful model system to study AD (Newman et al., 2014). 
Drosophila melanogaster, an invertebrate, has developed into an excellent model for human disease. The entire 
genome of Drosophila is sequenced, and the genetic machinery is highly conserved between flies and humans (Lenz 
et al., 2013). The fly genome has less genetic redundancy as compared to the humans (Bier, 2005; Lenz et al., 2013). 
Nearly 70% of fly genes are closely related to the human disease genes (Bier, 2005; Singh and Irvine, 2012). 
Therefore, using fruit fly to model human disease is practically beneficial. In addition, they are smaller in size and thus 
can be stored efficiently, and are cost effective. Drosophila can produce two generations in a month as the life cycle is 
short, and has a repertoire of genetic tools (Sarkar et al., 2016). In addition, the transgenic system is well established, 
which allows introduction of genes from other organism in the flies. It makes Drosophila an ideal model for studying 
age related progressive diseases like AD. Several models of AD have been developed in Drosophila. These include 
transgenic flies misexpressing human Aβ42, human Aβ40, human APP, β-site APP-cleaving enzyme, β-secretase and 
Presenilin, and Familial AD (Cauchi and van den Heuvel, 2006; Cao et al., 2008; Iijima and Iijima-Ando, 2008; Tare et 
al., 2011; Fernandez-Funez et al., 2013). These flies display several aspects of clinical AD neuropathology and 
symptoms including the generation of amyloid aggregates, external morphological abnormalities, dramatic 
neuroanatomical changes and defects in motor reflex behavior and memory. As a proof of concept, treatment with an 
inhibitor of γ-secretase can suppress these neurodegenerative phenotypes. Drosophila has also been used to model 
other neurodegenerative diseases like Parkinson’s disease, Huntington’s disease, fronto-temporal lobar degeneration, 
and amyotrophic lateral sclerosis (Bier, 2005; Pandey and Nichols, 2011; Singh and Irvine, 2012; Fernandez-Funez et 
al., 2013).
Lately, Drosophila eye has also been extensively used for modeling human disease (Singh and Irvine, 2012; Moran et 
al., 2013; Steffensmeier et al., 2013). Drosophila has a fully functional nervous system where function of vision, 
olfaction, learning and memory can be separated. Furthermore, the genes involved in eye development are 
structurally and functionally similar between flies and humans. The adult compound eye of Drosophila [Figure 4]A, 
develops from a mono-layer epithelium housed in the larva and referred to as the eye-antennal imaginal disc (Ready 
et al., 1976; Singh and Choi, 2003; Singh et al., 2005a, 2012; Kumar, 2011; Tare et al., 2013a). The larval eye 
imaginal disc metamorphose into a highly organized compound eye comprised of photoreceptor cells, cone cells, and 
pigment cells (Ready et al., 1976; Kumar, 2011, 2013; Singh et al., 2012; Tare et al., 2013a). The precise nature of the 
structure of Drosophila eye makes it highly sensitive to genetic manipulations that can be easily screened using a 
stereo microscope (Tare et al., 2013b; Singh et al., 2005b), which allows quick screening of large sample size (Singh 
and Choi, 2003; Singh et al., 2005a, b, 2006; Tare et al., 2013a). The Drosophila eye allows direct visualization of the 
cellular and developmental defects. Therefore, Drosophila eye can be used to mimic many neurodegenerative 
disorders including AD (Bier, 2005; Tare et al., 2011; Singh and Irvine, 2012; Moran et al., 2013; Cutler et al., 2015; 
Sarkar et al., 2016). Since it is easy to visualize the phenotypes in Drosophila eyes caused by neurodegeneration 
(Tare et al., 2013a), the Drosophila eye model can be used to study the different signaling pathways causing AD or 
other neurodegenerative disorders, and to screen for the therapeutic targets.{Figure 4}
The Drosophila model has a large repertoire of tools that allows expression of foreign genes along spatial and -
temporal axes. Using Gal4/UAS (upstream activating sequence) transgenic systems (Brand and Perrimon, 1993), 
human Aβ42 was misexpressed in the differentiating photoreceptor neurons of the developing eye (Tare et al., 2011; 
Moran et al., 2013; Steffensmeier et al., 2013). It resulted in accumulation of extracellular amyloid plaques, as 
evidenced by immuno-histochemical approaches. These human Aβ42 expressing eyes exhibited progressive 
neurodegenerative phenotype in the Drosophila eye [Figure 4]B as compared to the wild-type adult compound eye 
[Figure 4]A (Tare et al., 2011; Sarkar et al., 2016). This Aβ42 mediated neurodegeneration phenocopies AD like 
neuropathology in terms of progression of phenotype [Figure 4]A & [Figure 4]B. Thus, Drosophila eye model of Aβ42 
mediated neurodegeneration can be exploited for genome wide genetic screens or for screening chemical libraries for 
potential therapeutic targets. 
 Current Therapeutic Targets for AD
Presently, Food and Drug Administration approved drug regimen for AD help to treat the symptoms but do not cure the 
disease itself. The anti-inflammatory drugs (Aisen, 2000), like atorvastatin (Sparks et al., 2005), aspirin (AD2000 
Collaborative Group et al., 2008), and rosiglitazone (Harrington et al., 2011) have not shown the complete cure in 
improving the cognitive decline in AD patients. The AD patients have less acetylcholine neurotransmitter in the brain 
that results in loss of neurons. Therefore, cholinesterase inhibitors have been approved by Food and Drug 
Administration for AD treatment regimen (Gomes et al., 2018). But these drugs have side-effects like nausea, 
vomiting, diarrhea, muscle cramps, fatigue indigestion, weight loss, confusion and headache, and do not sure AD 
(Colovic et al., 2013). Hence, there is a need of medication, which has less side effects and can treat the disease by 
preventing the neuronal cell death. The available medicines for AD ameliorate the symptoms but cannot cure the 
disease altogether. Lately, there have been disappointing results from AD drug trials due to widespread drug failures 
and lack of diversity of novel targets (Goldman et al., 2018). Efforts are directed towards search for alternative 
treatment approaches, and among them screening for natural product library for potential therapeutic targets is on the 
forefront.
 Natural Products: Potential Targets for AD
The traditional herbal medicines that are compounds extracted from natural plant products can be less toxic, may 
have less side-effects and inexpensive than the synthetic drugs. Some plant products have medicinal properties for 
neurodegenerative diseases like anticholinesterase activities, anti-inflammatory, antioxidant, and neuroprotective 
function. Natural products like Lunasin, Polyphenols, Flavonoids, Alkaloids, and Tannins are potential therapeutic 
candidates for the AD (Zhang et al., 2008; Williams et al., 2011; Pany et al., 2014; Sarkar et al., 2018). Here we 
discuss some of the natural products that have demonstrated a potential in preventing neurodegeneration observed in 
AD in cell lines or in animal model systems.
Lunasin
Lunasin was first extracted in 1987 in Japan from soybean (Glycine max) seed, a staple in the diets of many cultures, 
while screening for the protease inhibitors. It is also found in other plants like wheat, barley, rye, amaranth and 
triticale. Lunasin, a thermostable protein, which should be ingested at optimum amount (Liu et al., 2014). Lunasin has 
antioxidant, anti-inflammatory and anti-cancer properties (Jones and Srivastava, 2014). Lunasin is the smaller subunit 
of the soybean 2S albumin protein [Figure 4]D. The gene GM2S-1 encodes methionine rich protein, signal peptide, a 
linker peptide and Lunasin which are post-translationally processed (Jones and Srivastava, 2014). It has 43 amino 
acid residues, a molecular weight of 5.5 kDa, and eight negatively charged aspartate residue sequence at the 
carboxyl end. Lunasin has four motifs: N-terminal domain, predicted helical region, arginine-glycine-aspartate (RGD) 
domain and poly-D tail [Figure 4]E. The function of N-terminal domain of Lunasin is unknown. The predicted helical 
domain binds to the chromatin. The poly D sequence acts as H3-H4 histone acetylation inhibitor. The amino acids 
preceded the poly D stretch are RGD, which helps in internalization of Lunasin into nucleus and in binding of Lunasin 
to the core histone proteins (Liu et al., 2014). The function of other peptides in Lunasin has not been defined. 
Lunasin can inhibit mitosis by increasing the expression of cyclin dependent kinases inhibitors like p21 and p27 
[Figure 5] (Dia and Gonzalez de Mejia, 2011; Jones and Srivastava, 2014). The cyclin dependent kinases play an 
important role in cell cycle and their misexpression results in cell cycle deregulation. Tumor suppressor genes regulate 
the cell cycle progression and are often downregulated in cancers. PTEN, a Tensin homolog and a tumor suppressor 
phosphatase, is mutated in cancer. Lunasin is found to increase the levels of PTEN in human breast cancer cells 
(MCF-7) inducing the apoptosis [Figure 5] (Pabona et al., 2012). Lunasin represses the expression of genes, which 
are involved in tumor suppression (Hsieh et al., 2017). Animal studies suggests that Lunasin has anti-inflammatory 
effects [Table 1] and [Figure 5] by inhibiting cytokines such as tumor necrosis factor α and interleukin-6. It also inhibits 
the release of nitric oxide (Liu and Pan, 2010). Hence, Lunasin may be potential therapeutic target for the disease 
where inflammation is observed.{Figure 5}{Table 1}
Drosophila eye model system has been used to study the effects of Lunasin in transgenic flies expressing high levels 
of human Aβ42 in differentiating retinal neurons of the eye (Sarkar et al., 2018). Targeted misexpression of Aβ42 in the 
developing retinal neurons of the flies showed glazed eye appearance and necrotic spots suggesting 
neurodegeneration (Sarkar et al., 2018). This study suggests that misexpression of Lunasin in the differentiating 
retinal neurons of the developing Drosophila eye can rescue Aβ42 mediated neurodegeneration [Figure 2] (Sarkar et 
al., 2018). Previously, it has been shown that activation of evolutionarily conserved Jun-N terminal kinase signaling 
pathway is involved in AD. Sarkar et al. (2018) reported that Lunasin downregulates Jun-N terminal kinase signaling to 
rescue Aβ42 mediated neurodegeneration. AD a neurodegenerative disorder exhibits neuro-inflammation due to 
production of the ROS [Figure 5]. Lunasin can be used as a potential therapeutic target for AD and further studies on 
vertebrate models will be helpful to discern its medical properties on mammals.
Polyphenols
Polyphenols derived from different plants are part of our daily diet, and have been reported to improve cognitive 
activities and reduce the neuropathology in animal models of AD (Wang et al., 2014). They have antioxidant property, 
which helps in scavenging ROS (Malar and Devi, 2014). Polyphenols can prevent formation of neurofibrillary tangles 
by preventing tau hyper-phosphorylation, which makes it potential target for AD [Figure 2] and [Table 1].
Curcumin, a polyphenol, extracted from Curcuma longa and has been used in Ayurveda medicines. Curcumin has 
been shown to inhibit the generation of Aβ42 oligomers and the plaques [Figure 2] and [Table 1] (Williams et al., 
2011). Administration of curcumin in AD animal model prevented neuro-inflammation, tau hyper-phosphorylation and 
protein kinase B (Akt)/glycogen synthase kinase 3 signaling pathway (Hoppe et al., 2013). It also helps in decreasing 
ROS by regulating pathways mediated neurodegeneration [Figure 2] (Doggui et al., 2013).
Resveratrol, a polyphenolic compound, has found to play role in activation of SIRT1, SIRT2 and SIRT3 (Sirtuins), 
which plays role in neuronal cell survival and longevity (Bastianetto et al., 2000; Rahman et al., 2006; Schirmer et al., 
2012). As a result, Sirtuins reduce the Aβ plaque aggregation in transgenic model of AD [Table 1] (Karuppagounder et 
al., 2009). Hyper-activation of Microglia triggers neuronal death. Resveratrol exhibits antioxidant effects in microglial 
cell line in hypoxia injury model. Thus, resveratrol may exhibit neuroprotective function by regulating microglia in brain 
(Song et al., 2014). Polyphenols have also been reported to lessen the mitochondrial dysfunction thereby preventing 
onset or delaying progression of neurodegeneration. 
Combination of polyphenol treatment has been found to be the novel treatment target for AD (Auti and Kulkarni, 
2018). A combination of three polyphenols like grape seed extract, resveratrol and Concord grape juice extract have 
been tested in mouse model of AD. They found that combination treatment proved to be better than the individual 
treatment in reducing amyloid content in the brain and thereby improving the cognitive impairment in AD mouse model 
(Wang et al., 2014). 
Flavonoids
Flavonoids are plant secondary metabolites, which are anti-oxidant, anti-amyloidogenic, anti-inflammatory and 
modulate cell-signaling pathways (Baptista et al., 2014; Bakhtiari et al., 2017). Approximately 128 flavonoids have 
been reported. They have acetylcholinesterase inhibitory activity proving to be a promising drug for AD (Auti and 
Kulkarni, 2018). Moreover, these phytochemicals can cross the blood-brain barrier, which has direct effect on the brain 
(de Andrade Teles et al., 2018). Flavonoids affect phosphatidylinositol 3-kinase/Akt pathway and mitogen activated 
protein kinase signaling pathway, which regulate expression of transcription factors involved in survival (Bakhtiari et 
al., 2017). Flavonoids reduce the toxic Aβ aggregation by inhibiting β-secretase and activate the- secretase activity 
[Figure 2] (Baptista et al., 2014). Additionally, it also prevents the formation of tau hyper-phosphorylation (Baptista et 
al., 2014). Another flavonoid, Quercitin (3,3′,4′,5,7-pentahydroxyflavone), can decrease the levels of ROS and inhibits 
apoptosis in young rats [Figure 2] (de Andrade Teles et al., 2018). Another study shows that quercitin blocks nuclear 
factor ĸB levels and hence reduces the inflammation (Pany et al., 2014). Catechin, derived from catechu, is a plant 
secondary metabolite. Catechins prevent Aβ42 accumulation and oxidative stress [Figure 2] and [Table 1] (Rezai-
Zadeh et al., 2005; Pervin et al., 2018). Kaempferol, a natural flavonoid, can be derived from variety of plants. Effect 
of Kaempferol on transgenic AD flies was found to decrease the oxidative stress and acetylcholinesterase activity 
[Table 1] (Beg et al., 2018). 
Alkaloids
Alkaloids are organic compounds that contain basic nitrogen atoms. Most of them are acetyl-cholinesterase and 
butylcholinesterase inhibitors (Konrath et al., 2013). Huperzine A, isolated from Huperzia serrate, has been used for 
memory enhancement in ancient Chinese medicine. Huperzine A, a specific and selective acetylcholinesterase 
inhibitor, showed increase in acetylcholine in rat brain (Zangara, 2003). It is also known to reduce Aβ aggregates in 
brain (Zhang et al., 2008). Additionally, Huperzine A, an N-methyl-D-aspartic acid receptor antagonist, reduces 
glutamate neurotoxicity. Hence, it reduces the synaptic loss and cell death of neurons [Table 1] (Auti and Kulkarni, 
2018). 
Nicotine, 3-(1-methyl-2-pyrrolidinyl) pyridine, is obtained from Nicotiana tobacum. Nicotine patches as well as 
injections have reported to improve the learning abilities in animals as well as AD patients. Since nicotine has adverse 
effects, it is important to assess the efficacy in AD patients [Table 1] (Levin and Simon, 1998; Nordberg et al., 2002; 
Newhouse et al., 2012; Auti and Kulkarni, 2018). Berberine, isoquinoline, have been used in Chinese and Ayurvedic 
medicine regimens. It is anti-inflammatory, anti-oxidant, anti-cancer, anti-depressants, and prevents Aβ42 plaque 
formation [Figure 2], [Table 1] (Durairajan et al., 2012; Cai et al., 2016).
Terpenes
Terpenes, aromatic molecules, are group of hydrocarbons that consist of repeats of isoprene units. Terpenes inhibit 
acetylcholinesterase activity and block the advanced glycation end product formation (Auti and Kulkarni, 2018). 
Triterpenes have anti-oxidative and anti-inflammatory activities. Gensenoside, which promotes health and longevity, 
have been studied for their effects on AD. Gensenoside prevents the Aβ42 levels by increasing Neprilysin gene 
expression [Figure 2] and [Table 1] (Yang et al., 2009). Moreover, Ginseng improves learning ability in aging brains of 
rodents. 
Ginkgolides, cyclic diterpenes, isolated from Ginkgo biloba. It has been shown that it promotes cell survival of neurons 
from synaptic damage by Synaptophysin, a presynaptic marker (Bate et al., 2008). It has been reported that 
Ginkgolide B can rescue Aβ induced apoptosis by promoting the synthesis of neurotrophic factor and reduces the cell 
death of neurons in the AD rats brains [Figure 2] (Serruys et al., 2011).
A triterpenoid, Platycodin D, which is present in the root extract of Platycodon Grandiflorus (balloon flower or Chinese 
bellflower) inhibits the Aβ42 plaques mediated neuronal loss [Figure 2]. Using rat PC12 cell lines (derived from 
phenochromocytoma of the rat adrenal medulla cells), it was shown that Platycodon Grandiflorus extract from root 
contains Platycodin D, can increase synaptogenesis in the hippocampus by activating mitogen activated protein 
kinase/extracellular regulated protein kinase pathway. Platycodon Grandiflorus extract from root can be studied further 
on AD models to test its therapeutic potential efficiency (Kim et al., 2017).
 Future of Natural Products As a Therapeutic Medicine
The use of medicinal plants as source of natural products to cure disease is a result of man experimenting by trial and 
error for hundreds of centuries, searching for available foods for the treatment of diseases. The natural products have 
been used as medicines throughout history in the form of traditional medicines, remedies, potions and oils. Before the 
discovery of chemical based drug formulations, majority of drug regimens were natural product based across the 
civilizations. The earliest records dates as early as Mesopotamia (2600 B.C.) where oils from Cupressus 
semperviviens (Cypress) and Commiphos species (myrrh) were used to treat cough and colds. These treatments are 
still in use today. In India, Curcurmin or Azadirachta indica (Neem), a member of Meliaceae family that has rich source 
of antioxidants has been extensively used in Ayurveda medicine. These natural products have been extensively used 
in Indian, Chinese and Unani medicine because of their property of scavenging ROS, and their pivotal role in 
anticancer management and other diseases. It has been shown to modulate various growth regulatory pathways 
including p53, phosphate and tension homology deleted on chromsome ten (pTEN), phosphatidylinositol 3-kinase/Akt, 
etc. (Alzohairy, 2016).
It is evident that discovery of natural products will be beneficial on multiple levels. Many of these bioactive natural 
products are still unidentified. Natural plant products are available in everyday diet and they are the part of the 
traditional medicines in Indian Ayurveda and Chinese medicines. The fruits, vegetables and grains prevent the onset 
or delay the onset of the disease and promote healthy aging. These natural products also reduce the risk of AD 
(Howes et al., 2003). The bioactive compounds with pharmacological effects have been extensively studied to cure 
various neurological diseases. These phytochemicals have better pharmacological effects and can cross the blood-
brain barrier and high bioavailability. They are safe and effective as compared to other available drugs in the market. 
As a result, they might be considered to be an effective alternative to the current drugs. 
 Conclusions
The natural phytochemicals with pharmacological effects can serve as potential therapeutic treatments for AD. These 
natural products may reduce ROS, or prevent the toxic Aβ42 plaque production. Alternatively, these products may act 
downstream of Aβ42 plaque accumulation and modulate the aberrant signaling events that are triggered due to Aβ42 
plaques in AD. Studies in animal model system strongly suggest that some of these natural products can cure and 
prevent AD effectively [Figure 2] and [Table 1]. 
As the age expectancy will increase due to advancement in medical science, the prevalence of the neurodegenerative 
diseases will increase in aging population. It has been seen that changes in lifestyle, change in food habits, excessive 
stress due to work or environmental conditions have aided to increase in frequency of neurodegenerative disease like 
AD. The management or finding cures for AD is an issue to target multiple causative agents of the disease (Goldman 
et al., 2018). Understanding the molecular mechanism of the disease by using animal model system in vivo studies 
would be helpful in identifying the potential therapeutic targets. Various animal models are being used to study the 
mechanism of action of these products at molecular level. Scientists have turned to natural products for drug 
development for neurodegenerative diseases like AD, because of their medicinal properties. The phytochemicals 
seem to be promising and potential therapeutic targets for neurodegenerative diseases like AD. The strength of usage 
of natural products lie in their bioavailability. Thus, following a strict diet regimen with emphasis on natural products 
with potential medicinal properties have promising expectation for finding cures for AD.
Interestingly, in humans by the time AD is detected, the disease has progressed significantly. At this stage, a critical 
number of neurons are already lost, which manifests as the loss of cognitive functions in the patient. Since many of 
the neurons are post mitotic, they cannot be replaced by normal cell division. Therefore, efforts are being directed 
towards approaches to recover and regenerate the damaged or lost neurons to restore the lost cognitive functions 
(Felsenstein et al., 2014). Blocking Aβ42 mediated neurodegeneration at the time when AD is detected, will only 
prevent the further loss of neurons after that stage. However, it will not recover dead neurons and as a result, there 
will be no recovery of cognitive functions lost due to neurodegeneration. Thus, there is a need to utilize these 
established animal models to screen for potential therapeutic targets which can generate regeneration response in the 
neuronal population of AD patients.[96] 
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